In April, we celebrate
CRSwNP Awareness Day!a

>88,000 patients have been prescribed DUPIXENT to treat their CRSwNP.b
This month, we’re honoring the HCPs who help them find relief.

aCRSwNP Awareness Day is April 24, 2024.

bData on file, Sanofi US. IQVIA weekly NSOB; data through December 2023.

US.DUP.24.02.0182

MAKE DUPIXENT YOUR FIRST-CHOICE BIOLOGIC

RELIEVED
Symptoms
Sustained through:

1 YEAR improvement in sense of smell (UPSIT) and nasal congestion3,b,c

Seen as early as:

2 DAYS to improvement in nasal congestion (post hoc analysis; result is descriptive)4,d

3 DAYS to improvement in Loss of Smell (post hoc analysis; result is descriptive)4,e,f

SEE MORE DATA
REDUCED
FUTURE SURGERY AND/OR SCS USE
  • 83% reduction in the need for sinus surgery through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46])2
  • 74% reduction in the need for SCS use through Week 52 (HR: 0.26 [95% CI: 0.18, 0.38])2

Individually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.

SEE MORE DATA
REGAINED
QUALITY OF LIFE
As measured by SNOT-22g
  • 35% improvement at Week 4
    vs 14% with placebo3,h
  • 58% improvement at Week 52 vs 14% with placebo (P<0.0001)3,i
SEE MORE DATA

 

Week 24 (SINUS-52): 51% improvement in NC score with DUPIXENT (pooled arms) vs 15% improvement with placebo; LSM difference vs placebo -0.87 (95% CI: -1.03, -0.71) (coprimary endpoint).2,3

Week 24 (SINUS-24): -1.34 improvement in NC score with DUPIXENT vs -0.45 improvement with placebo; LSM difference vs placebo -0.89 (95% CI: -1.07,-0.71) (coprimary endpoint).2

bWeek 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): 10.30 (95% CI: 8.50, 12.10) (9.53 from a baseline score of 13.46 vs -0.77 from a baseline score of 13.78, respectively).3

cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively).3

dLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).4,5

eLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02). Patient-reported Loss of Smell score.4,5

fWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81).2

gThe SNOT-22 score is calculated from a patient questionnaire where 22 symptoms are rated from 0 (“no problem”) to 5 (“as bad is it can be”) based on the severity and frequency of each particular item.2,3

hWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=295, pooled arms): -10.57 (95% CI: -14.47, -6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively).3

iWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -20.96 (95% CI: -25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively).3

Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.

CI, confidence interval; HR, hazard ratio; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SNOT-22, 22-item Sino-Nasal Outcome Test; UPSIT, University of Pennsylvania Smell Identification Test.

Unique
Mechanism
of
Action (MOA)

Only DUPIXENT targets both IL‑4
and IL‑13 signaling, two of the key
drivers of local and systemic
type 2 inflammation.2,6,7,a

aThe mechanism of dupilumab action has not been
definitively established.2

Multiple Administration
Options

Work with your patients to decide
how to administer DUPIXENT:
either administer at home or
administer in the office.2

A patient may self-inject DUPIXENT—or a caregiver may
administer DUPIXENT—after training has been provided
by a healthcare provider on proper subcutaneous
injection technique using the pre-filled syringe or pre-
filled pen.2

Safety
Data

View safety data across
clinical trials.

Support can make all the difference. DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Check Formulary Status in Your Area

See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.

LOOK UP COVERAGE
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.
CONTACT A REP